$IONS News Article - Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients https://marketwirenews.com/news-releases/ioni...53979.html
Ionis Pharmaceuticals, Inc. (IONS) Stock Research Links
My Twitter: WhyteStocks